EyeWorld Asia-Pacific December 2021 Issue

two great strengths of this study. Given this study’s retrospective nature, there was no standardized protocol among the study groups. Medical and surgical decisions were individualized to each patient and surgeon. Only interventions performed in the operating room were included in this study. In particular, this study eÝcluded inoffice needling and likely underestimated the rates of needling in the XEN group. This study’s focus was on the 90-day postoperative period, and therefore did not offer insight into late-term complications that may occur. Other studies have also looked at longer-term outcomes following MIGS. In a retrospective study, eyes were followed 1 year after XEN implantation, and 6 % had transient hypotony, 10 % had 2 or more Snellen lines lost, and 16 % required a second glaucoma procedure regardless of ab interno or ab externo approach. 3 In a prospective study of eyes with cataract and mild to moderate primary open angle glaucoma, Hydrus implantation reduced the probability of incisional glaucoma surgery from 3.9 % to 0.6 % in a 3-year period as compared to cataract surgery alone. 4 One large randomized study of 152 eyes compared Hydrus and iStent and found a statistically significant decreased reoperation rate (0 versus 3.9 %) and reduced medication use in the Hydrus group. 5 The panelists in the ASCRS Journal Club pointed out that even in cases of recently diagnosed, mild glaucoma, a percentage of patients will progress to severe disease. /his is eÝemplified Ly the LiGHT study, in which 1.8 % of ocular hypertension patients required a traditional glaucoma surgery within 3 years despite no evidence of glaucomatous damage at presentation. 6 In the future, MIGS may be offered to ocular hypertensives as early surgical options to decrease risk of progression to advanced disease. More long-term outcomes data is needed to further analyze the safety profiles among the MIGS procedures and compared to traditional glaucoma surgery. /he authors puLlished the first study of short-term reoperation rates after MIGS. True to its definition] - has a faÛoraLle safety profile compared to traditional glaucoma surgery. The XEN group had the highest rate of reoperation. MIGS continues to emerge as an important surgical option for eyes with glaucoma. EWAP References 1. Tham YC, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology . 2014;121:2081–2090. 2. Chu CK, et al. Reoperations for complications within 90 days after glaucoma surgery. J Glaucoma . 2020;29:344–346. 3. Tan NE, et al. Comparison of safety and efficacy Letween aL interno and ab externo approaches to XEN Gel Stent placement. Clin Ophthalmol . 2021;15:299–305. {. Ƃhmed ] et al. /hreeyear findings of the HORIZON trial: a Schlemm canal microstent for pressure reduction in primary open-angle glaucoma and cataract. Ophthalmology . 2021;128:857–865. 5. Ahmed IIK, et al. A prospective randomized trial comparing Hydrus and iStent microinvasive glaucoma surgery implants for standalone treatment of open-angle glaucoma: the COMPARE study. Ophthalmology . 2020;127:52–61. 6. Gazzard G, et al. Selective laser traLeculoplasty Ûersus eye drops for first line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre Reoperation for complications within 90 days of minimally invasive glaucoma surgery Wesam Shamseldin Shalaby, MD, Joseph Bechay, BS, Jonathan Myers, MD, Daniel Lee, MD, Reza Razeghinejad, MD, Natasha Nayak Kolomeyer, MD, L. Jay Katz, MD, Aakriti Garg Shukla, MD J Cataract Refract Surg. 2021;47(7):886–891. Purpose: To describe reoperations that occurred within 90 days of minimally invasive glaucoma surgery (MIGS) at a single institution over a 30-month period. Setting: Tertiary care hospital. Design: Retrospective case series. Methods: Charts of adult patients who underwent trabecular microbypass stents, gel microstents, and goniotomy procedures (including gonioscopy-assisted transluminal trabeculotomy) from October 1, 2017 to March 15, 2020 at Wills Eye Hospital were examined. Outcome measures were unanticipated reoperations within the first ä days after - procedures and the complications that led to these reoperations. Results: 448 MIGS procedures were performed on 436 eyes of 348 patients over a 30-month period by 6 glaucoma surgeons. Of these, 206 (46.0 %) were trabecular microbypass stents (198 iStent/iStent inject [Glaukos], 8 Hydrus [Ivantis]), 152 (33.9 %) were gel microstents, 90 Óä.£ ¯® were goniotomy procedures. omLined phacoemulsification took place in 256 (58.7 %) eyes. Reoperation within 90 days took place in 23/436 eyes (5.3 %), including 16/152 eyes in the gel microstent group (10.5 %), 4/198 eyes in the iStent/ iStent inject group (2.0 %), 3/90 eyes in the goniotomy group (3.3 %). Indications for reoperation were elevated intraocular pressure (IOP) in 16/23 eyes (69.6 %), gel microstent tip exposure with wound leakage in 3/23 eyes (13 %), and early gel microstent encapsulation without elevated IOP in 1/23 eye (4.3 %). 2/23 eyes (8.7 %) required reoperation for lens complications while 1/23 eye (4.3 %) had elevated IOP and aphakia requiring reoperation. Conclusion: /he rate of reoperation within the first ä days after MIGS was low. Elevated IOP and complications associated with gel microstents were the main indications for reoperation. randomised controlled trial. Lancet . 2019;393:1505–1516. Editors’ note: Dr. Chow is Residency Program Director, Yale Eye Center, New Haven, Connecticut. Dr. Linderman and Dr. Ray are ophthalmology residents, Yale Eye Center, New Haven, Connecticut. The ASCRS Journal Club is a virtual, complimentary CME offering exclusive to ASCRS members that brings the experience of a lively discussion of two current articles from the Journal of Cataract & Refractive Surgery to the viewer. Co-moderated by Nick Mamalis, MD, and Leela Raju, MD, the July session featured a presentation by Jake McMillin, MD, author of ‘Accuracy of intraocular lens calculation formulas vor yanged intrascleral intraocular lens fiÝation Üith douLleneedle techniµue°½ The second manuscript, ‘Reoperation for complications within 90 days of minimally invasive glaucoma surgery’ was presented by Hetal Ray, MD, resident, Yale Eye Center. To view the July Journal Club session, visit ascrs. org/clinical-education/ journal-club/ schedule/july-2021.